Kenneth Krogulski - 16 Nov 2023 Form 4/A - Amendment Insider Report for CUMBERLAND PHARMACEUTICALS INC (CPIX)

Role
Director
Signature
Kenneth J. Krogulski by /s/ John Hamm as attorney-in-fact
Issuer symbol
CPIX
Transactions as of
16 Nov 2023
Net transactions value
+$3,526
Form type
4/A - Amendment
Filing time
06 Dec 2023, 17:01:41 UTC
Date Of Original Report
30 Nov 2023
Previous filing
17 Nov 2023
Next filing
28 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $114 +66 +0.03% $1.73 227,925 16 Nov 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $512 +280 +0.12% $1.83 228,205 17 Nov 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $456 +268 +0.12% $1.70 228,473 20 Nov 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $220 +125 +0.05% $1.76 228,598 21 Nov 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $487 +280 +0.12% $1.74 228,878 22 Nov 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $705 +379 +0.17% $1.86 229,257 27 Nov 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $208 +124 +0.05% $1.68 229,381 28 Nov 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $285 +165 +0.07% $1.73 229,546 29 Nov 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $538 +324 +0.14% $1.66 229,870 30 Nov 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May16, 2023.